Evidence map›Paper›PMID 27873105›Full record

ArticleJournal of clinical immunology2017

Newborn Screening for Severe Primary Immunodeficiency Diseases in Sweden-a 2-Year Pilot TREC and KREC Screening Study.

Michela Barbaro, Annika Ohlsson, Stephan Borte, Susanne Jonsson, Rolf H Zetterström, Jovanka King, Jacek Winiarski, Ulrika von Döbeln, Lennart Hammarström

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Journal of clinical immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06711354 (B-cell Depletion in Offspring to Women With MS and Rituximab Treatment Before or During Pregnancy), which is not on this map. Cited by 83 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 2 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06711354 unknown statusnot on this mapstarted 2025, after this paper: background citation

B-cell Depletion in Offspring to Women With MS and Rituximab Treatment Before or During Pregnancy

Typeobservational_patient_registrySponsorRegion StockholmRan2025 to 2025Enrolled111ConditionsMultiple Sclerosis, B-Cell Deficiency, Offspring, Adult, ImmunosuppressionArmsAnti-CD20 Monoclonal Antibody
3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 2 syntheses or guidelines pooled it, 141 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Optimizing TREC- and KREC-based newborn screening: Risk-stratified algorithms significantly reduce referrals.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026
    Article
  9. Transient B cell lymphopenia revealed by KRECs newborn screening: Post-screening referral strategies, clinical course, and follow-up.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 3 countries.

Michela BarbaroCentre for Inherited Metabolic Diseases, Karolinska University Hospital Solna, SE-17176, Stockholm, Sweden.
Annika OhlssonCentre for Inherited Metabolic Diseases, Karolinska University Hospital Solna, SE-17176, Stockholm, Sweden.
Stephan BorteDepartment of Clinical Immunology, Karolinska University Hospital Huddinge, SE-14186, Stockholm, Sweden.
Susanne JonssonCentre for Inherited Metabolic Diseases, Karolinska University Hospital Solna, SE-17176, Stockholm, Sweden.
Rolf H ZetterströmCentre for Inherited Metabolic Diseases, Karolinska University Hospital Solna, SE-17176, Stockholm, Sweden.
Jovanka KingDepartment of Clinical Immunology, Karolinska University Hospital Huddinge, SE-14186, Stockholm, Sweden.
Jacek WiniarskiDepartment of Clinical Technology and Intervention, Karolinska Institutet, SE-14186, Stockholm, Sweden.
Ulrika von DöbelnCentre for Inherited Metabolic Diseases, Karolinska University Hospital Solna, SE-17176, Stockholm, Sweden. ulrika.vondebeln@karolinska.se.
Lennart HammarströmDepartment of Clinical Immunology, Karolinska University Hospital Huddinge, SE-14186, Stockholm, Sweden. lennart.hammarstrom@ki.se.
Karolinska University Hospital · SEKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Newborn screening for severe primary immunodeficiencies (PID), characterized by T and/or B cell lymphopenia, was carried out in a pilot program in the Stockholm County, Sweden, over a 2-year period, encompassing 58,834 children. T cell receptor excision circles (TREC) and kappa-deleting recombination excision circles (KREC) were measured simultaneously using a quantitative PCR-based method on DNA extracted from dried blood spots (DBS), with beta-actin serving as a quality control for DNA quantity. Diagnostic cutoff levels enabling identification of newborns with milder and reversible T and/or B cell lymphopenia were also evaluated. Sixty-four children were recalled for follow-up due to low TREC and/or KREC levels, and three patients with immunodeficiency (Artemis-SCID, ATM, and an as yet unclassified T cell lymphopenia/hypogammaglobulinemia) were identified. Of the positive samples, 24 were associated with prematurity. Thirteen children born to mothers treated with immunosuppressive agents during pregnancy (azathioprine (n = 9), mercaptopurine (n = 1), azathioprine and tacrolimus (n = 3)) showed low KREC levels at birth, which spontaneously normalized. Twenty-nine newborns had no apparent cause identified for their abnormal results, but normalized with time. Children with trisomy 21 (n = 43) showed a lower median number of both TREC (104 vs. 174 copies/μL blood) and KREC (45 vs. 100 copies/3.2 mm blood spot), but only one, born prematurely, fell below the cutoff level. Two children diagnosed with DiGeorge syndrome were found to have low TREC levels, but these were still above the cutoff level. This is the first large-scale screening study with a simultaneous detection of both TREC and KREC, allowing identification of newborns with both T and B cell defects.

Indexed as

Neonatal ScreeningFemaleGenetic TestingGestational AgeHumansInfant, NewbornMaleMultiplex Polymerase Chain ReactionPhenotypeReal-Time Polymerase Chain ReactionReceptors, Antigen, T-CellRecombination, GeneticRisk FactorsSequence DeletionSevere Combined ImmunodeficiencySwedenReceptors, Antigen, T-CellKRECNewborn screeningprimary immunodeficiency diseasessevere combined immunodeficiencyTREC

Identifiers

PMID27873105
PMCPMC5226987
OpenAlexW2555840471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.